Patent EP0399321A2 successfully refreshed from Google Patents.
EP0399321A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Gel filtration of heat treated factor VIII
Assignee: Bayer Corp
•
Filing: 1990-05-12
•
Granted: —
•
Expires: 2010-05-12
Abstract
Abstract Highly purified antihemophilic factor is produced by a process comprising a PEG precipitation step, a gel filtration step and a heat treating virus inactivation step. Al(OH)₃ adsorption and PEG precipitation carried out at room temperature allow processing to proceed directly to a gel filtration step.
Inventors
- 👤 Christian Dr. Goelker
- 👤 Bernd Dr. Bockskopf
- 👤 William Brockway
- 👤 Richard L. Seng
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 19:33
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
78 words
A process for the production of a concentrate of antihemophilic factor (AHF) from cryoprecipitate comprising the steps of: (a) dissolving said cryoprecipitate; (b) removing non-AHF proteins by precipitation with polyethylene glycol (PEG); (c) heat treating said AHF for viral inactivation; then (d) passing said AHF through a gel filtration column containing a size exclusion resin to remove said chemical and to concentrate said AHF to at least 35 units of Factor VIII activity per ml of pooled concentrate.
Claim 2
Dependent Claim
78 words
A process for the production of a concentrate of antihemophilic factor (AHF) from cryoprecipitate comprising the steps of: (a) dissolving said cryoprecipitate; (b) removing non-AHF proteins by precipitation with polyethylene glycol (PEG); (c) heat treating said AHF for viral inactivation; then (d) passing said AHF through a gel filtration column containing a size exclusion resin to remove said chemical and to concentrate said AHF to at least 35 units of Factor VIII activity per ml of pooled concentrate.
Claim 3
Dependent Claim
17 words
The process of claim 1 wherein said resin has a fractionation range from 300 to 15,000,000 daltons.
Claim 4
Dependent Claim
24 words
The process of claim 1 further comprising the step of precipitating AHF with a mixture of glycine and NaCl prior to said gel filtration.
Claim 5
Dependent Claim
16 words
The process of claim 1 wherein PEG is added in an amount of 2 - 5%.
Claim 6
Dependent Claim
27 words
The process of claim 1 further comprising the step of ultrafiltering said concentrate to obtain at least 100 units of Factor VIII activity per ml of concentrate.
Claim 7
Dependent Claim
55 words
A process for the production of antihemophilic factor concentrate (AHF) comprising the steps of: (a) preparing a cryoprecipitate; (b) removing non-AHF proteins by precipitation to form a solubilized AHF pool; (c) passing said pool through a gel filtration column; and (d) heating AHF obtained from said column in a solution in the presence of sucrose.
Claim 8
Dependent Claim
55 words
A process for the production of antihemophilic factor concentrate (AHF) comprising the steps of: (a) preparing a cryoprecipitate; (b) removing non-AHF proteins by precipitation to form a solubilized AHF pool; (c) passing said pool through a gel filtration column; and (d) heating AHF obtained from said column in a solution in the presence of sucrose.
Claim 9
Dependent Claim
15 words
The process of claim 6 further comprising the step of concentrating said pool by ultrafiltration.
Claim 10
Dependent Claim
21 words
The process of claim 7 wherein said heating in the presence of sucrose takes place in 1.2 to 0.6 mg/ml sucrose.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.